These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 26793346)

  • 21. Telmisartan plus amlodipine in patients with moderate or severe hypertension: results from a subgroup analysis of a randomized, placebo-controlled, parallel-group, 4 x 4 factorial study.
    Littlejohn TW; Majul CR; Olvera R; Seeber M; Kobe M; Guthrie R; Oigman W;
    Postgrad Med; 2009 Mar; 121(2):5-14. PubMed ID: 19332958
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Angiotensin Receptor Blocker and Calcium Channel Blocker Preventing Atrial Fibrillation Recurrence in Patients with Hypertension and Atrial Fibrillation: A Meta-analysis.
    Ma H; Jiang H; Feng J; Gan Y
    Cardiovasc Ther; 2021; 2021():6628469. PubMed ID: 34104205
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and safety of two fixed-dose combinations of S-amlodipine and telmisartan (CKD-828) versus S-amlodipine monotherapy in patients with hypertension inadequately controlled using S-amlodipine monotherapy: an 8-week, multicenter, randomized, double-blind, Phase III clinical study.
    Ihm SH; Jeon HK; Cha TJ; Hong TJ; Kim SH; Lee NH; Yoon JH; Yoon N; Hwang KK; Jo SH; Youn HJ
    Drug Des Devel Ther; 2016; 10():3817-3826. PubMed ID: 27920497
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Renoprotective effects of renin-angiotensin system inhibitor combined with calcium channel blocker or diuretic in hypertensive patients: A PRISMA-compliant meta-analysis.
    Cheng Y; Huang R; Kim S; Zhao Y; Li Y; Fu P
    Medicine (Baltimore); 2016 Jul; 95(28):e4167. PubMed ID: 27428210
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term effects of irbesartan on plasma aldosterone concentration and left atrial volume in hypertensive patients.
    Masaki M; Komamura K; Goda A; Hirotani S; Otsuka M; Nakabo A; Fukui M; Fujiwara S; Sugahara M; Lee-Kawabata M; Tsujino T; Koshiba M; Masuyama T
    J Cardiol; 2014 Mar; 63(3):205-10. PubMed ID: 24060523
    [TBL] [Abstract][Full Text] [Related]  

  • 26. ARB candesartan and CCB amlodipine in hypertensive patients: the CASE-J trial.
    Ogihara T; Fujimoto A; Nakao K; Saruta T;
    Expert Rev Cardiovasc Ther; 2008 Oct; 6(9):1195-201. PubMed ID: 18939907
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Differential effectiveness of ARB plus CCB therapy and high-dose ARB therapy in high-risk elderly hypertensive patients: subanalysis of the OSCAR study.
    Kim-Mitsuyama S; Ogawa H; Matsui K; Jinnouchi T; Jinnouchi H; Arakawa K;
    Hypertens Res; 2015 Mar; 38(3):199-207. PubMed ID: 25471234
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of Long- and Intermediate-Acting Dihydropyridine Calcium Channel Blockers in Hypertension: A Systematic Review and Meta-Analysis of 18 Prospective, Randomized, Actively Controlled Trials.
    Chaugai S; Sherpa LY; Sepehry AA; Kerman SRJ; Arima H
    J Cardiovasc Pharmacol Ther; 2018 Sep; 23(5):433-445. PubMed ID: 29739234
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical outcomes of renin angiotensin system inhibitor-based dual antihypertensive regimens in chronic kidney disease: a network meta-analysis.
    Cho M; Choi CY; Choi YJ; Rhie SJ
    Sci Rep; 2023 Apr; 13(1):5727. PubMed ID: 37029191
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and safety of angiotensin II type 1 receptor blocker/calcium channel blocker combination therapy for hypertension: focus on a single-pill fixed-dose combination of valsartan and amlodipine.
    Miura S; Saku K
    J Int Med Res; 2012; 40(1):1-9. PubMed ID: 22429340
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Randomized trial of an increased dose of calcium channel blocker or angiotensin II type 1 receptor blocker as an add-on intensive depressor therapy in type 2 diabetes mellitus patients with uncontrolled essential hypertension: the ACADEMIE Study.
    Imaizumi S; Shiga Y; Ogawa M; Sako H; Nagata Y; Matsunaga A; Shirotani T; Hoshino F; Yahiro E; Uehara Y; Morito N; Tanigawa H; Shimono D; Fukushima M; Sugihara H; Norimatsu K; Kusumoto T; Saku K; Miura SI;
    Heart Vessels; 2019 Apr; 34(4):698-710. PubMed ID: 30406819
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparative Effects of an Angiotensin II Receptor Blocker (ARB)/Diuretic vs. ARB/Calcium-Channel Blocker Combination on Uncontrolled Nocturnal Hypertension Evaluated by Information and Communication Technology-Based Nocturnal Home Blood Pressure Monitoring　- The NOCTURNE Study.
    Kario K; Tomitani N; Kanegae H; Ishii H; Uchiyama K; Yamagiwa K; Shiraiwa T; Katsuya T; Yoshida T; Kanda K; Hasegawa S; Hoshide S
    Circ J; 2017 Jun; 81(7):948-957. PubMed ID: 28321001
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Two multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hypertension.
    Philipp T; Smith TR; Glazer R; Wernsing M; Yen J; Jin J; Schneider H; Pospiech R
    Clin Ther; 2007 Apr; 29(4):563-80. PubMed ID: 17617280
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Leg edema with (S)-amlodipine vs conventional amlodipine given in triple therapy for hypertension: a randomized double blind controlled clinical trial.
    Galappatthy P; Waniganayake YC; Sabeer MI; Wijethunga TJ; Galappatthy GK; Ekanayaka RA
    BMC Cardiovasc Disord; 2016 Sep; 16(1):168. PubMed ID: 27586538
    [TBL] [Abstract][Full Text] [Related]  

  • 35. I-COMBINE study: assessment of efficacy and safety profile of irbesartan/amlodipine fixed-dose combination therapy compared with amlodipine monotherapy in hypertensive patients uncontrolled with amlodipine 5 mg monotherapy: a multicenter, phase III, prospective, randomized, open-label with blinded-end point evaluation study.
    Bobrie G;
    Clin Ther; 2012 Aug; 34(8):1705-19. PubMed ID: 22853848
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparative efficacy and safety profile of amlodipine 5 mg/losartan 50 mg fixed-dose combination and amlodipine 10 mg monotherapy in hypertensive patients who respond poorly to amlodipine 5 mg monotherapy: an 8-week, multicenter, randomized, double-blind phase III noninferiority study.
    Kang SM; Youn JC; Chae SC; Park CG; Yang JY; Kim MH; Hong TJ; Kim CH; Kim JJ; Shin DG; Jeong JW; Yoon JH; Park SH; Kwon J; Cho SY
    Clin Ther; 2011 Dec; 33(12):1953-63. PubMed ID: 22136978
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety of dual calcium channel blockade for the treatment of hypertension: a meta-analysis.
    Alviar CL; Devarapally S; Nadkarni GN; Romero J; Benjo AM; Javed F; Doherty B; Kang H; Bangalore S; Messerli FH
    Am J Hypertens; 2013 Feb; 26(2):287-97. PubMed ID: 23382415
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A systematic review and meta-analysis of aliskiren and angiotension receptor blockers in the management of essential hypertension.
    Zhenfeng Zheng ; Huilan Shi ; Junya Jia ; Dong Li ; Shan Lin
    J Renin Angiotensin Aldosterone Syst; 2011 Jun; 12(2):102-12. PubMed ID: 21059822
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of valsartan versus amlodipine in diabetic hypertensive patients with or without previous cardiovascular disease.
    Yamashita K; Kondo T; Muramatsu T; Matsushita K; Nagahiro T; Maeda K; Shintani S; Murohara T
    Am J Cardiol; 2013 Dec; 112(11):1750-6. PubMed ID: 24035165
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prospective randomized study of the tolerability and efficacy of combination therapy for hypertensive chronic kidney disease: results of the PROTECT-CKD study.
    Hayashi M; Uchida S; Kawamura T; Kuwahara M; Nangaku M; Iino Y;
    Clin Exp Nephrol; 2015 Oct; 19(5):925-32. PubMed ID: 25680887
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.